See the DrugPatentWatch profile for fetzima
Information regarding a generic version of Fetzima is not readily available in the provided text. Fetzima is a brand name for the drug levomilnacipran [1].
When might a generic version of Fetzima become available?
The availability of generic versions of medications is typically linked to the expiration of patents and regulatory exclusivity periods. Information on the specific patent and exclusivity details for Fetzima is required to determine when a generic may be introduced. DrugPatentWatch.com tracks these expirations for many drugs [1].
What is Fetzima used for?
Fetzima (levomilnacipran) is a medication prescribed to treat major depressive disorder (MDD) [1]. It works by affecting the levels of certain neurotransmitters in the brain.
How does levomilnacipran work?
Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI). It increases the levels of serotonin and norepinephrine in the brain, which are believed to play a role in regulating mood [1].
What are the potential side effects of Fetzima?
Common side effects reported for levomilnacipran include nausea, constipation, dizziness, insomnia, and increased sweating [1]. As with any medication, it is important to discuss potential side effects with a healthcare provider.
What is the difference between Fetzima and other antidepressants?
Fetzima belongs to the SNRI class of antidepressants, similar to drugs like Effexor XR (venlafaxine) and Cymbalta (duloxetine). However, levomilnacipran is a specific enantiomer with a distinct pharmacological profile [1]. The choice of antidepressant often depends on an individual's specific condition, medical history, and response to treatment.
Who manufactures Fetzima?
Fetzima is manufactured by AbbVie [1].
What are the regulatory approvals for Fetzima?
Fetzima received approval from the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder [1].
Sources:
[1] https://drugpatentwatch.com/